Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease
NCT ID: NCT00917527
Last Updated: 2012-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
77 participants
INTERVENTIONAL
2009-06-30
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Atorvastatin
Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
Atorvastatin
Atorvastatin
Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* the siblings of premature coronary heart disease(male\<55years old, female\<65years old: Framingham Heart Study)patients admitted relevant hospital
Exclusion Criteria
* Any woman of childbearing potential who is pregnant, seeking to become pregnant or suspects that she may be pregnant.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yonsei University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hyuk-Jae Chang
Yonsei University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hyuk-Jae Chang, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Cardiology Division, Severance Cardiovascular Hospital, Yonsei University College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Severance Cardiovascular Hospital, Yonsei University College of Medicine
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hyuk-Jae Chang, MD, PhD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Nasir K, Michos ED, Rumberger JA, Braunstein JB, Post WS, Budoff MJ, Blumenthal RS. Coronary artery calcification and family history of premature coronary heart disease: sibling history is more strongly associated than parental history. Circulation. 2004 Oct 12;110(15):2150-6. doi: 10.1161/01.CIR.0000144464.11080.14. Epub 2004 Oct 4.
Hong SJ, Chang HJ, Park S, Kang DR, Shin S, Cho IJ, Shim CY, Hong GR, Ha JW, Chung N. Impact of atorvastatin treatment in first-degree relatives of patients with premature coronary artery disease with endothelial dysfunction: a double-blind, randomized, placebo-controlled crossover trial. Clin Cardiol. 2013 Aug;36(8):480-5. doi: 10.1002/clc.22152. Epub 2013 Jun 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20090615
Identifier Type: -
Identifier Source: org_study_id